USP to Introduce New Viral Clearance Chapter
The United States Pharmacopeia is preparing a new general chapter, 1050.1, titled “Design, Evaluation, and Characterization of Viral Clearance Procedures.” This new standard will address the design and validation of viral clearance steps in bioprocessing, directly impacting process validation and documentation requirements for viral vector manufacturing.
- This chapter provides detailed, practical guidance on experimental design for viral clearance studies, a level of specificity that was intentionally absent from the broader ICH Q5A R1 guideline upon which the foundational USP chapter <1050> is based. - Officially implemented on August 1, 2016, chapter <1050.1> was developed as a companion to <1050> to offer current best practices without altering the harmonized language of the original ICH Q5A document. - The chapter emphasizes the need for a comprehensive and detailed viral clearance plan to be documented *before* studies begin, specifying critical operating parameters, sampling plans, and the rationale for worst-case conditions, all of which are key data points for digital batch records and LIMS. - It provides specific examples and approaches for validating common viral inactivation methods (e.g., pH or solvent/detergent treatment) and removal techniques like filtration and column chromatography, which directly informs the design of automated and well-characterized manufacturing processes. - While ICH Q5A(R2) considers a 1 to 3 log10 reduction suitable, the USP sets a higher bar, requiring a log reduction factor of at least 4 for a process step to be considered an effective viral clearance step. - The development of this guidance was led by a USP Viral Clearance Expert Panel, chaired by Dr. Robert G. Bell, as part of the work of the General Chapters-Biological Analysis Expert Committee. - This standard is part of a broader USP framework for viral safety that also includes chapters on virology test methods (<1237>) and virus testing of human plasma (<1240>), providing a comprehensive set of guidelines for manufacturers. - Unlike its parent chapter, <1050.1> includes an updated and harmonized table of example viruses that can be used in clearance studies, reflecting more recent potential contaminants of concern for cell culture-derived products.
